Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0156 | 1 | 1 |
Brugia malayi | RNA binding protein | 0.0058 | 0.3423 | 0.3909 |
Brugia malayi | Muscleblind-like protein | 0.0138 | 0.8756 | 1 |
Echinococcus multilocularis | muscleblind protein | 0.0138 | 0.8756 | 0.8756 |
Brugia malayi | MH2 domain containing protein | 0.011 | 0.6896 | 0.7876 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.011 | 0.6896 | 0.7876 |
Echinococcus multilocularis | muscleblind protein 1 | 0.0138 | 0.8756 | 0.8756 |
Schistosoma mansoni | tar DNA-binding protein | 0.0058 | 0.3423 | 0.3423 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0058 | 0.3423 | 0.3909 |
Echinococcus multilocularis | tar DNA binding protein | 0.0058 | 0.3423 | 0.3423 |
Loa Loa (eye worm) | hypothetical protein | 0.0138 | 0.8756 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0058 | 0.3423 | 0.3423 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.011 | 0.6896 | 0.7876 |
Schistosoma mansoni | tar DNA-binding protein | 0.0058 | 0.3423 | 0.3423 |
Schistosoma mansoni | tar DNA-binding protein | 0.0058 | 0.3423 | 0.3423 |
Echinococcus multilocularis | geminin | 0.0156 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0058 | 0.3423 | 0.3909 |
Loa Loa (eye worm) | TAR-binding protein | 0.0058 | 0.3423 | 0.3909 |
Schistosoma mansoni | hypothetical protein | 0.0156 | 1 | 1 |
Echinococcus granulosus | muscleblind protein | 0.0138 | 0.8756 | 0.8756 |
Loa Loa (eye worm) | hypothetical protein | 0.0138 | 0.8756 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0058 | 0.3423 | 0.3423 |
Schistosoma mansoni | tar DNA-binding protein | 0.0058 | 0.3423 | 0.3423 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0058 | 0.3423 | 0.3909 |
Brugia malayi | TAR-binding protein | 0.0058 | 0.3423 | 0.3909 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.